States along the west coast have already passed laws to allow for “controlled” interstate commerce – when federal law changes.
Many groups’ work, from CANNRA to the National Academies of Sciences, Engineering, and Medicine, informed a federal recommendation to reclassify cannabis.
State Medical Cannabis Programs, Booming Research, Informed HHS Recommendation to Reclassify Cannabis
Newly released documents from the Dept. of Health and Human Services detail the agency’s recommendation to the DEA to put cannabis in Schedule III.
The second meeting of the Committee on the Public Health Consequences of Changes in the Cannabis Policy Landscape is underway this week. Here’s what happened on day one.
There’s no consistency among states about how to disclose recalled cannabis products.
The CDC, NIOSH, and the Massachusetts Department of Public Health published reports and bulletins this week following their investigations into a cannabis worker’s death in 2022.
FDA researchers published an article this week titled “From Our Perspective: FDA’s 50 Years of Experience with Cannabis Research Helping to Support Tomorrow’s Cannabis Drug Development.”
American Enterprise Institute Hosts Cannabis Conversation: “You Can Either Get on the Bus or You Can Get Hit By It.”
The center-right think tank hosted a cannabis policy discussion in D.C. on Wednesday focused on the future of federal reforms.
The “experimental data product” focused on excise sales tax revenue is the Bureau’s most comprehensive cannabis data collection effort to date.
The scheduling review, prompted by Pres. Biden in October, could reshape the cannabis policy landscape in the U.S. Now, the DEA will decide.
The two-day FDLI conference focused on thorny questions in cannabis regulation, and included the FDA and other regulators.
On Thursday, the FDA pushed its desire to work with Congress on cannabinoid product rules, including delta-8 THC.
The FDA is seeking a “harm reduction framework” as it works with Congress on a path for CBD, according to the agency’s Cannabis Product Committee lead.
Amid Booming Cannabis Industry, State Insurance Regulators Call for “Safe Harbor” in New White Paper
A working group of the National Association of Insurance Commissioners plans to present the final paper at the Association’s Summer National Meeting in August.
Will the 2023 Farm Bill fix some of the confusion caused by the 2018 version that legalized hemp? State regulators and industry regulators hope Congress acts fast.
Norman Birenbaum spoke about the FDA’s cannabis-related efforts during a discussion on Thursday hosted by the Council for Federal Cannabis Regulation.